AbbVie’s Risankizumab (SKYRIZI®) shows positive phase III results in Patients with Crohn’s Disease
AbbVie announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing risankizumab 360 mg ...
Read moreAbbVie announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing risankizumab 360 mg ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.